- Areas of Interest
- Techniques
- Systems
- Products & Services
- Informatics
- Science & Education
- Company
- Support
The Myeloid Panel enables concurrent analysis of both DNA and RNA from blood and bone marrow samples in a single assay to study biomarkers associated with hematologic malignancies. The panel covers relevant targets for these major myeloid disorders: acute myeloid leukemia (AML), myeloid dysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), and juvenile myelomonocytic leukemia (JMML). Key features include:
The Myeloid Panel is part of an integrated workflow that includes AmpliSeq for Illumina polymerase chain reaction (PCR)-based library preparation, Illumina sequencing by synthesis (SBS), NGS technology, and automated analysis.
The ready-to-use panel saves you the time and effort of identifying targets, designing primers, and optimizing panels.
| Instrument | Recommended Number of Samples | Read Length |
|---|---|---|
| MiniSeq System | Samples per run (mid output): 4 DNA, 32 RNA, 3 combined samples (based
on >95% at 500x minimum coverage) Samples per run (high output): 12 DNA, 96 RNA, 11 combined samples (based on >95% at 500x minimum coverage) |
2 x 151 bp 2 x 151 bp |
| MiSeq System | Samples per run with v2 reagents: 7 DNA, 60 RNA, 6 combined samples Samples per run with v3 reagents: 12 DNA, 96 RNA, 11 combined samples |
2 x 151 bp 2 x 151 bp |
| AmpliSeq for Illumina Myeloid Panel | AmpliSeq for Illumina Cancer Hotspot Panel v2 | TruSight Myeloid Sequencing Panel | |
|---|---|---|---|
| Assay Time | 5.5 – 7.5 hours (library prep only; doesn't include library quantification, normalization, or pooling time) | 5 hours (library prep only; doesn't include library quantification, normalization, or pooling time) | 8 hours |
| Cancer Type | Hematologic | Pan-Cancer, Solid Tumor | Hematologic |
| Content Specifications | Targets biomarkers across 69 genes (40 key DNA target genes, 29 RNA fusion driver genes, and 5 gene expression levels) | Hotspot regions of 50 genes with known associations to cancer | Targets 54 genes associated with myeloid malignancies. Probes amplify 568 amplicons from tumor suppressor genes and mutational hotspots. |
| Description | Targeted panel to study 40 DNA genes, 29 RNA fusion driver genes, and 5 gene expression levels associated with myeloid cancers. | Somatic analysis research into hotspot regions of 50 cancer-related genes. | For somatic mutation detection studies in myeloid malignancies. |
| Hands-On Time | < 1.5 hours | < 1.5 hours | 3 hours |
| Input Quantity | 20 ng high-quality DNA; 10 ng high-quality RNA (10 ng recommended per pool) |
1–100 ng (10 ng recommended per pool) | 50 ng |
| Method | Amplicon Sequencing , Targeted DNA Sequencing , Targeted RNA Sequencing | Amplicon Sequencing , Targeted DNA Sequencing | Amplicon Sequencing , Targeted DNA Sequencing |
| Multiplexing | Up to 96-plex | 96 dual index combinations | Up to 96-plex |
| Nucleic Acid Type | RNA, DNA | DNA | DNA |
| Specialized Sample Types | Blood, FFPE Tissue, Low-Input Samples | Blood, FFPE Tissue | Not FFPE-Compatible |
| Species Category | Human | Human | Human |
Sample Identification with the AmpliSeq for Illumina Sample ID Panel Application Note
Application Note | HTM
AmpliSeq for Illumina Myeloid Panel Data Sheet
Data Sheet | HTM
Assay targeting multiple variant types, including tumor mutational burden (TMB) and microsatellite instability (MSI), even from low-quality samples.
Targeted panel investigating the exonic regions of 409 genes with known associations to cancer.
Targeted custom research panels optimized for sequencing specific targets or genomic content of interest.
